Anyway So now you expect that it will take NICE a year or two to give the approval. However you would be wrong. NHS England has entered into a commercial agreement that allows NHS patients in England immediate access to the drug. Yesterday doctors within England have been given the greenlight to prescribe oral cladribine.
The other Home nations will hopefully follow soon.
This is the first MS disease-modifying therapy that has gone straight to a positive final recommendation in the NICE appraisal process, involving just one committee meeting. NICE seemed to conclude that cladribine tablets are less costly than other treatments and require less frequent dosing and monitoring requirements. Therefore, they appear to believe that it is cost-effective
So this is good news for People with MS and also for TeamG because their work will have clear Impact.
It will now be interesting in what happens with ocrelizumab and how NICE will handle its appraisal.
CoI: None…yet…ProfG and DrK multiple